<unk>  (MGRS) is a group of kidney disorders that are characterized an abnormal secretion of a monoclonal protein (M protein) from plasma cell clones or other B-cell clones in patients who do not meet the diagnostic criteria for multiple myeloma (MM) or any other B-cell malignancies. MGRS is considered a type of monoclonal gammopathy of undetermined significance (MGUS), as kidney is one of the most commonly targeted organs in MGUS. The lesions in MGRS fall under three main categories; lesions with organized deposits, lesions with non-organized deposits, and Lesions without immune deposits. MGRS must be differentiated from other diseases that cause monoclonal gammopathy such as Multiple myeloma, Chronic lymphocytic leukemia (CLL), and Lymphoplasmacytic lymphoma. Renal biopsy is the mainstay in the evaluation of MGRS. Following suspicion of MGRS, lab evaluation of kidney function should be performed by renal function testing, urinanalysis, and a complete metabolic panel. The main and most effective therapeutic modality is clone-directed therapy, based on the nature of the clone that releases the nephrotoxic monoclonal immunoglobulins; B-cell or plasma cell. In case of end-stage kidney disease, kidney transplantation is the best option.
Monoclonal gammopathy of renal significance
Monoclonal gammopathy of undetermined significance
Familial renal amyloidosis
Renal amyloidosis
Paraprotein-related kidney disease
Familial amyloidosis
Beta-2 microglobulin related amyloidosis
Multiple myeloma